The Street is treating $19 billion as a new normal; the filing argues for caution. In its annual report for fiscal 2022, filed February 24, 2023, Moderna reported full-year revenue of about $19.26 billion — roughly flat against about $18.47 billion in 2021, and worlds away from about $803 million in 2020. The shape of that three-year arc is the whole argument.
Here is the single fact that undercuts the bull case: that revenue is overwhelmingly one product line. A company can be enormously profitable and dangerously concentrated at the same time, and Moderna’s filings are candid that dependence on its lead product is a material risk. R&D of roughly $3.3 billion in 2022 — up sharply from prior years — is the company spending its windfall trying to build what comes after.
The contrarian’s job is to read the trajectory, not the snapshot. Revenue that plateaued between 2021 and 2022 on a single concentrated source is exactly the setup where the next leg is uncertain. The 10-K does not forecast a decline — but it also does not promise the peak holds, and it spends real money hedging against the possibility that it won’t.
So the steelman and the skeptic both live in this filing. The bull sees $19 billion and a multibillion-dollar reinvestment engine; the bear sees a flat, concentrated peak funded by a demand cycle that may not repeat. As of early 2023, which one is right is unresolved — the document gives you the evidence, not the verdict.
Every figure above is drawn from the company's primary SEC filing — surfaced through EdgarBeast, the SEC filing data API and evidence index — and verifiable against the filing on sec.gov.